

13 Mar 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: big pharma and Ukraine; new gene therapy deal for Novartis; Phase III hemophilia success for Sanofi; J&J's Gorsky's views on Asia innovation; and a look at pharma's deal-making activity last year.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 11 March 2022, including: big pharma and Ukraine; new gene therapy deal for [Novartis AG](#); Phase III hemophilia success for [Sanofi](#); [Johnson & Johnson](#)'s Gorsky's views on Asia innovation; and a look at pharma's deal-making activity last year.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Big Pharma Braces For Modest Financial And Clinical Trial Disruption In Eastern Europe](#)" - Scrip, 9 Mar, 2022.)

(Also see "[Novartis Bets Big On Next-Gen Gene Therapy With Voyager Pact](#)" - Scrip, 8 Mar, 2022.)

(Also see "[Sanofi Looks To Dominate \\$5bn Hemophilia A Factor Market After Trial Success](#)" - Scrip, 9 Mar, 2022.)

(Also see "[J&J's Gorsky Puts Spotlight On Big Picture Potential Of Asia, New Technologies](#)" - Scrip, 7

Mar, 2022.)

(Also see "[Who Were Big Pharma's Top Deal-Makers In 2021?](#)" - Scrip, 4 Mar, 2022.)

[Click here to explore this interactive content online](#) ✨